Cann Group (CAN.AX) Akcija Kursas
Cann Group Kursas
Pajamos augo 79,5 % per metus per pastaruosius 11 metus iki 8,56 mln. AUD. Cann Group grynoji marža dabar yra 237,1 %, išaugo nuo −412,9 % prieš kelerius metus.
Cann Group akcijos kaina
Gaukite šiuos duomenis per Eulerpool API
100 000 užklausų/mėn. nemokamai · be kortelės
Cann Group akcija ir akcijų analizė
Dažnai užduodami klausimai apie Cann Group akciją
Cann Group Ltd is an Australian company that operates in the medicinal cannabis industry. Its business model revolves around cultivation, manufacturing, and distribution of pharmaceutical-grade cannabis products and providing services to the medicinal cannabis sector. With a focus on research and development, Cann Group aims to support healthcare professionals and patients by developing high-quality therapeutic products derived from cannabis plants. The company's expertise lies in the production of standardized cannabis cultivars, extraction, and development of new formulations to meet the evolving needs of the medical industry. Cann Group Ltd strives to establish itself as a leading player in the medicinal cannabis market.
Cann Group Ltd is primarily active in the cannabis industry.
The main competitors of Cann Group Ltd in the market include other companies involved in the production and distribution of medical cannabis and cannabis-related products. Some significant competitors of Cann Group Ltd may include AusCann Group Holdings Ltd, Althea Group Holdings Ltd, and Little Green Pharma Ltd. These companies operate in the same industry and focus on the cultivation, manufacturing, and sale of medical cannabis products. Cann Group Ltd competes with these companies to gain market share, secure partnerships, and expand their customer base in the rapidly growing cannabis industry.
Cann Group Ltd is an Australian company that specializes in cultivating and producing medical cannabis. Established in 2014, Cann Group was the first to be granted a license to cultivate and research cannabis for medicinal purposes in Australia. With a strong commitment to quality and compliance, the company has built state-of-the-art facilities and established strategic partnerships to expand its operations. Cann Group is dedicated to providing safe and effective cannabis-based products to improve patient outcomes and is at the forefront of the rapidly growing medicinal cannabis industry in Australia.
Cann Group Ltd has achieved several significant milestones in its operations. Firstly, the company became the first Australian business to obtain a license to cultivate medicinal cannabis for research purposes in 2017. This achievement positioned Cann Group Ltd as a pioneer in the country's emerging medicinal cannabis industry. Additionally, the company successfully completed its first commercial cannabis harvest in 2018, marking another important milestone. Furthermore, Cann Group Ltd obtained its crucial Manufacture License in 2019, allowing the company to produce and distribute medicinal cannabis products in Australia. These milestones highlight Cann Group Ltd's commitment to advancing the availability and quality of medicinal cannabis within the country's market.
Cann Group Ltd is primarily present in Australia.
Cann Group Ltd, a leading Australian medicinal cannabis company, embodies a strong set of values and corporate philosophy. The company is committed to producing high-quality medical cannabis products to improve the lives of patients. Cann Group values innovation and sustainability, constantly seeking new ways to enhance their cultivation and manufacturing processes. With a focus on research and development, they aim to continually expand their product offerings and provide effective and safe treatments. Cann Group Ltd prides itself on its dedication to investors, transparency, and regulatory compliance, ensuring a trustworthy and reliable approach to business.
5 analitikai šiuo metu vertina Cann Group akciją: 4 rekomenduoja pirkti, 1 laikyti ir 0 parduoti.
Pagal dabartinį kursą Cann Group akcija kainuoja 0,00 EUR (0,01 AUD).
Cann Group akcija (CAN.AX) kotiruojama 3 biržose, įskaitant: ASX (CAN.AX), Frankfurt (CVJ.F).
Cann Group Ltd is an Australian company specializing in the medical cannabis market. Its business model involves producing, developing, and distributing cannabis for medical use. The company serves various segments, such as the market for human medical products, the veterinary sector, and the recreational and wellness sector. The company is well positioned to benefit from the growing demand for medical cannabis, CBD products for pets, and recreational products.
pelnas Cann Group yra 8,56 mln. AUD. Šis skaičius grindžiamas dabartiniais finansiniais duomenimis ir atspindi įmonės verslo rezultatus.
grynasis pelnas Cann Group yra 20,30 mln. AUD. Grynasis pelnas atspindi įmonės pelningumą po visų išlaidų atimties.
Kainų ir nuomos santykis (KGV) Cann Group šiuo metu yra 0,36. KGV lygina dabartinę akcijos kainą su pelnu už akciją ir padeda investuotojams įvertinti Cann Group akcijos vertę.
Kainų ir pardavimų santykis (KUV) Cann Group šiuo metu yra 0,85. KUV lygina rinkos kapitalizaciją su metinėmis pajamomis ir yra Cann Group akcijos įvertinimo metrika.
Eulerpool kokybės balas Cann Group yra 3/10.
Cann Group ISIN yra AU000000CAN2. ISIN (International Securities Identification Number) yra pasaulinė unikali vertybinių popierių identifikacijos sistema.
Cann Group WKN yra A2DSUQ. WKN (Wertpapierkennnummer) yra šešiaženklė vokiška vertybinių popierių identifikacijos sistema.
Cann Group prekybos žymė yra CAN.AX. Ši biržos žymė naudojama Cann Group akcijoms prekiauti biržoje.
Cann Group akcija
Cann Group Pagrindiniai konkurentai
Cann Group Biržos simbolis
Cann Group FIGI
Visos Cann Group pagrindinės charakteristikos ir giluminė analizė
Mūsų akcijų analizė Cann Group akcijai apima svarbius finansinius rodiklius, tokius kaip apyvarta, pelnas, P/E santykis, P/S santykis, EBIT, taip pat informaciją apie dividendes. Be to, mes nagrinėjame aspektus, tokius kaip akcijos, rinkos kapitalizacija, skolos, nuosavas kapitalas ir įsipareigojimai Cann Group. Jei ieškote išsamesnės informacijos šiais klausimais, mūsų poskyriuose galite rasti išsamias analizes: